Source-grounded facts extracted from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter ended March 31, 2026 results: revenue $749 million, net income $27 million. Guidance reaffirmed.
“First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year • First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year”
Lee A. Shapiro departed as Director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Mr. Shapiro will fulfill the remainder of his term as member of the Board of Directors and the effective date of his departure will be the Company’s Annual Meeting of Shareholders, June 10, 2025.”
Thomas L. Tran was appointed as Class II director at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On August 20, 2024, the Board of Directors (the "Board") of Clover Health Investments, Corp. ("Clover" or the "Company") appointed Thomas L. Tran, to serve as a Class II director of the Board.”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported the first quarter ended March 31, 2024 results: revenue $346.9 million, net income $23.2 million. Guidance raised.
“exceeding its expectations on several key operating metrics and highlighting significant progress on its path to profitability. For the first quarter 2024, total revenue was $346.9 million, with GAAP net loss from continuing operations improving to $23.2 million. Adjusted EBITDA improved to a profit of $6.8 million, as compared to the prior year period loss of”
Terrence Ronan departed as Interim Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“Mr. Kuipers will succeed Terrence Ronan, the Company’s current Interim Chief Financial Officer, who will continue in his role as Interim Chief Financial Officer until Mr. Kuipers becomes Chief Financial Officer, and thereafter cease to serve as the Company’s principal financial officer and principal accounting officer.”
Peter Kuipers was appointed as Chief Financial Officer at CLOVER HEALTH INVESTMENTS, CORP. /DE.
“On April 22, 2024, Clover Health Investments, Corp. (the “Company”) announced that Peter Kuipers will become Chief Financial Officer of the Company, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the day after the filing of the Company’s Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024, as approved by the Board of Directors of the Company on April 16, 2024.”
CLOVER HEALTH INVESTMENTS, CORP. /DE received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 2, 2024, Clover Health Investments, Corp. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s Class A common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Common Stock, which continues to trade on”
CLOVER HEALTH INVESTMENTS, CORP. /DE reported fourth quarter and full year ended December 31, 2023 results: revenue $510.3 million, net income net loss of $70.5 million. Guidance initiated.
“will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights. For the fourth quarter 2023, the Company reported revenue of $510.3 million and net loss of $70.5 million, with full-year revenue of $2,033.7 million and net loss of $213.4 million. Adjusted EBITDA during 2023 improved to a loss of $19.1 million in the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.